Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tucatinib

tucatinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tucatinib

5 trials tracked of tucatinib: 1 in phase 3 or 4.

5Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 4
  1. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
  2. Phase 2 A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Completed
  3. Phase 2 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Completed
  4. Phase 2 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Completed
  5. Phase 2 Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Capmatinib identified as a promising candidate for repurposing against Mpox via in silico screening
Infectious Disease Guideline
Capmatinib identified as a promising candidate for repurposing against Mpox via in silico screening Computer models identify potential new drugs to fight Mpox
This guideline provides an in silico study identifying capmatinib, nebivolol, and tucatinib as potential candidates for targeting MPXV thymi…
Researchers used computer simulations to identify three existing drugs that might be repurposed to treat Mpox infections.
Frontiers Sep 14, 2026
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC
Oncology RCT
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC Trial shows Tucatinib improves progression-free survival for metastatic breast cancer
This Phase III randomized controlled trial of 654 patients with HER2+ metastatic breast cancer found that adding tucatinib to trastuzumab an…
Adding tucatinib to a standard two-drug combination may help patients with HER2+ metastatic breast cancer live longer without their disease …
Jun 12, 2026